CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 88 enrolled
Drug / intervention
IX-01 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02232425
NCT02232425Phase 2Completed
CompareCT.gov

An 8-Week, Double-Blind, Placebo-Controlled Parallel Group Study to Evaluate the Effect of IX-01 on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Lifelong Premature Ejaculation

Ixchelsis Limited·interventional·Posted Sep 5, 2014·Updated Aug 17, 2020

In Brief

A Phase 2 clinical trial evaluating IX-01 and Placebo for Premature Ejaculation. Completed, enrolled 88 participants across 10 sites in 2 countries.

Detailed Summary

The purpose of this study is to determine the effectiveness of IX-01 in men with lifelong premature ejaculation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPremature Ejaculation
CountriesAustralia, United States
CollaboratorsCarelon Research, Novotech (Australia) Pty Limited, ICON plc, PHT Corporation

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 5, 2014
Enrollment StartSep 1, 2014
Primary CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 11.8 years ago

Interventions

IX-01drug

Placebodrug